Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 08/27/21 → 07/19/23 |
Funding
- Regeneron Pharmaceuticals Incorporated: $69,288.62
Covid-19 Clinical Research: A Phase 2A, Open-Label Study Assessing Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Single-Dose Subcutaneous or Intramuscular Anti-Spike (S) SARS-COV-2 Monoclonal Antibodies (Casirivimab and Imd
- Nachman, Sharon (PI)
- Beneri, Christy (CoPI)
- Handel, Andrew (CoPI)
Project: Research